You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 166 No. 13, July 10, 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Editor's Correspondence
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Etanercept or Infliximab: The Patient’s Considerations—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We appreciate the comments of Sherrick. We agree that medication decision making is complex and that shared decision making with patients is an essential aspect of good patient care. However, research on medical decision making suggests that the majority of physicians (65% in one study1) do not discuss medication expenses with patients. Furthermore, if financial considerations from the patient perspective alone were the primary factor determining biologic drug prescription decisions, one might expect that the proportion of patients with public insurance who received prescriptions for etanercept would be smaller than the 26% observed in our sample.

Among the models that attempt to explain whether and how physicians factor their patients' insurance plans into prescribing decisions, the modal insurance model is one of the strongest.2 In this model, the extent to which physicians' prescribing decisions are influenced by medical insurance coverage is based on the modal—or most frequently . . . [Full Text of this Article]


AUTHOR INFORMATION
Esi Morgan DeWitt, MD, MSCE; Henry A. Glick, PhD; Daniel A. Albert, MD; Frederick Wolfe, MD



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Etanercept or Infliximab: The Patient’s Considerations
Robert C. Sherrick
Arch Intern Med. 2006;166(13):1418.
EXTRACT | FULL TEXT  

Patient-Physician Communication About Out-of-Pocket Costs
G. Caleb Alexander, Lawrence P. Casalino, and David O. Meltzer
JAMA. 2003;290(7):953-958.
ABSTRACT | FULL TEXT  

Association of Managed Care Market Share and Health Expenditures for Fee-for-Service Medicare Patients
Laurence C. Baker
JAMA. 1999;281(5):432-437.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.